- Home
- ERH vs KZIA Comparison
ERH vs KZIA Comparison
Compare ERH & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERH | KZIA |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.6M | 100.8M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | ERH | KZIA |
|---|---|---|
| Price | $11.57 | $12.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 25.0K | ★ 228.4K |
| Earning Date | 01-01-0001 | 06-04-2026 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.91 | $3.30 |
| 52 Week High | $13.07 | $17.40 |
Technical Indicators
Market Signals| Indicator | ERH | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 29.89 | 49.92 |
| Support Level | $11.62 | $5.71 |
| Resistance Level | $11.96 | $14.82 |
| Average True Range (ATR) | 0.22 | 1.05 |
| MACD | -0.11 | -0.29 |
| Stochastic Oscillator | 9.26 | 14.47 |
Price Performance
Historical ComparisonAbout ERH Allspring Utilities and High Income Fund
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.